Introduction: The level of the presynaptic protein growth-associated protein 43 (GAP-43) in cerebrospinal fluid (CSF) has previously been shown to be increased in Alzheimer's disease (AD) and thus may serve as an outcome measure in clinical trials and facilitate earlier disease detection.
Background
Alzheimer's disease (AD) patients constitute a heterogeneous group, and patients with other neurodegenerative diseases such as frontotemporal lobar degeneration (FTD), dementia with Lewy bodies (DLB), and Parkinson's disease (PD) often display similar symptoms and mixed pathologies, which complicates the diagnosis [1, 2] . In addition to clinical evaluation, three core cerebrospinal fluid (CSF) biomarkers are currently used for diagnosis of AD; the 42 amino acid form of amyloid b (Ab 42 ), total-tau (T-tau), and *Corresponding author. phosphorylated tau (P-tau), reflecting amyloid pathology, neurodegeneration, and tangle pathology, respectively, are included in the diagnostic criteria for AD [3, 4] . Recently, disease-modifying drugs targeting Ab pathology, such as b-secretase inhibitors and the anti-Ab antibody aducanumab, have shown promising results [5, 6] highlighting an increasing need to correctly identify patients with AD pathology. Furthermore, such therapeutics is expected to be most effective at the early stages of AD before neuronal damage is too widespread.
It is known that pathological changes due to AD occur long before clinical symptoms appear. Therefore, it is important to diagnose patients as early as possible. It is widely recognized that synaptic dysfunction is an early core feature of AD and synaptic dysfunction and loss is highly correlated to cognitive decline [7] [8] [9] [10] . Thus, additional biomarkers reflecting synaptic dysfunction and loss may further improve differential diagnosis, be useful as outcome markers in clinical trials, provide novel disease stage information, and enable earlier diagnosis in combination with the core biomarkers.
Growth-associated protein 43 (GAP-43) is a presynaptic protein highly expressed during neuronal development and synaptogenesis and thereafter in the hippocampus and association cortices in the adult human brain [11] [12] [13] . Furthermore, GAP-43 is involved in the regulation of axonal outgrowth, synaptic plasticity, and learning and memory functions [14] [15] [16] [17] [18] [19] , and previous postmortem brain studies of GAP-43 reported decreased protein expression in frontal cortex and regional increases in the hippocampus of patients with AD [20] [21] [22] . In a recent explorative study including 280 proteins, it was shown that the fluorescence intensity per bead identity and sample for CSF GAP-43 was increased in preclinical and clinical AD compared to controls, while there were no significant changes in PD or DLB patients compared to controls [23] . However, assay characterization was not provided. Previous CSF quantification of GAP-43 in the early 2000s showed a decrease in PD but normal or only slightly increased concentration in AD compared to neurological controls [24, 25] . Discrepancies between the studies may be due to assay differences or the lack of knowledge at the time regarding differential diagnosis leading to mixed patient cohorts. Current knowledge on differential diagnosis allows for more homogeneous patient cohorts, which increases the chances of finding actual AD-specific biomarkers. Therefore, we developed and validated a novel enzyme-linked immunosorbent assay (ELISA) for quantification of GAP-43 in CSF and analyzed a large, wellcharacterized cohort including controls and clinically diagnosed AD patients and other dementia patients. A subpopulation of patients was neuropathologically assessed for amyloid, tau, a-synuclein, TDP pathology, and neuron loss in several different brain regions allowing for the first time an evaluation of associations between CSF GAP-43 concentration and several dementia pathologies. Furthermore, GAP-43 CSF concentration was tested for association with global cognition and decline over a 2-year period using the Mini-Mental State Examination (MMSE) score. The following hypotheses were tested: (1) CSF GAP-43 is especially affected in AD and useful for differential diagnosis; (2) CSF GAP-43 quantification is associated to cognitive decline; and (3) CSF GAP-43 is associated with AD pathology.
Methods

Participants
Pilot study
The pilot study included 15 AD patients and 12 controls. Demographics are summarized in Supplementary Table 1 . Ab 42 , T-tau, and P-tau were used for neurochemical classification of the patients into AD or control groups.
Clinical validation study
The clinical validation study included 662 participants from the University of Pennsylvania Integrated NeuroDegenerative Disease Database [26] , comprising participants without signs of neurodegenerative diseases serving as controls (n 5 43), mild cognitive impairment (MCI) (n 5 84), AD (n 5 275), amyotrophic lateral sclerosis (ALS) (n 5 53, of which ALS with MCI n 5 3, ALS with FTD n 5 9), behavioral variant FTD (bvFTD, n 5 39), noncognitively impaired PD (n 5 28), PD with MCI (n 5 14), PD with dementia (n 5 15), DLB (n 5 27), logopenic variant of primary progressive aphasia (lvPPA, n 5 10), semantic dementia variant of primary progressive aphasia (svPPA, n 5 16), progressive nonfluent aphasia variant of primary progressive aphasia (naPPA, n 5 15), progressive supranuclear palsy (n 5 18), corticobasal syndrome (n 5 19), and posterior cortical atrophy (PCA, n 5 6) patients. CSF sampling was performed according to standard operating procedures of the Alzheimer's Disease Neuroimaging Initiative (http:// www.adni-info.org/).
MMSE score was available for 593 subjects. Two-year follow-up MMSE scores were available for 305 subjects, and the decline in MMSE score per year was used to analyze the association between GAP-43 and cognitive decline.
In 93 patients, Braak neurofibrillary tau staging and Consortium to Establish a Registry for Alzheimer's Disease (CE-RAD) score was performed as previously described [26] . Furthermore, postmortem examination and scoring of tau, thioflavin/amyloid, a-synuclein, and TDP-43 pathology, as well as amyloid angiopathy, gliosis, and neuron loss, was carried out on brain sections from 17 brain regions: amygdala, cornu ammonis/subiculum-hippocampus, entorhinal cortex-hippocampus, midfrontal cortex, angular gyrus, superior-midtemporal cortex, anterior cingulate cortex, occipital (visual, calcarine) cortex, caudate/putamen, globus pallidus, thalamus, midbrain, substantia nigra-midbrain, pons, locus coeruleus-pons, medulla, and dentate nucleuscerebellum. Sections were processed and histologically (thioflavin S) or immunohistochemically stained (phosphorylated tau, a-synuclein, TDP-43) and graded using a fivepoint scale (0 5 none, 0.5 5 rare, 1 5 mild, 2 5 moderate, 3 5 severe) as previously described [26, 27] . GAP-43 concentrations across this scale were compared for the mentioned stains across the 17 brain regions, after merging data from points 0 and 0.5 due to low numbers.
Ethics
The pilot study on leftover aliquots from clinical routine analyses followed a procedure approved by the Ethics Committee at University of Gothenburg (EPN140811). The clinical validation study was conducted in accordance with the provisions of the Helsinki declaration and approved by regional ethics committee.
AD biomarker quantification
In the clinical validation study, quantification of CSF Ttau, P-tau, and Ab42 was performed on the Luminex platform (Luminex Corporation, Austin, TX) using the multiplexed AlzBio3 (Fujirebio, Ghent, Belgium) kit as instructed in kit inserts. For biomarker correlation analysis, ALS patients were merged, due to the low number of patients per group. Patients with variants of primary progressive aphasia were similarly merged for correlation analysis.
Brain homogenization, western blotting, and immunoprecipitation
Brain samples were taken from the superior parietal gyrus of AD subjects. Homo Q3 genization of brain tissue, western blotting, and immunoprecipitation of CSF was performed as previously described [28] , with minor modifications (see Supplementary Material for a detailed description). Full-length recombinant GAP-43 protein was produced in house (see Supplementary Material) and compared to endogenous GAP-43 protein by western blotting in the brain and CSF.
In-house GAP-43 sandwich ELISA
The ELISA was developed in house combining the mouse monoclonal GAP-43 antibody NM4 (Fujirebio) and a polyclonal GAP-43 antibody (ABB-135, Nordic Biosite, T€ aby, Sweden) with a C-terminal epitope. For detailed description, see Supplementary Material. The analyses were performed by board-certified laboratory technicians blinded to clinical information. During sample runs in the clinical evaluation study, the repeatability CV% of control samples, with the concentrations 3157 pg/mL and 857 pg/mL, was 5.5% versus 11% and the interassay CV% was 6.9% versus 15.6% across 18 ELISA plates.
In-house GAP-43 ELISA validation
The performance of the novel ELISA was evaluated using leftover CSF samples from clinical routine of the Neurochemistry laboratory, Sahlgrenska University Hospital, M€ olndal, Sweden (see Supplementary Material for an evaluation of precision, LLOQ, recovery, and sample dilution linearity).
Statistical analysis
Statistical analysis was performed using SPSS version 23.00 (IBM, NY, USA) and GraphPad Prism 7.0 (GraphPad Inc., CA, USA). As the biomarker data were not normally distributed, nonparametric statistics were used. Unless otherwise stated, demographics and clinical characteristics were summarized using medians and interquartile ranges for biomarkers and analyzed by Mann-Whitney U-test, Kruskal-Wallis test, and chi-square test. Comparisons of biomarker concentrations were performed using KruskalWallis test and Spearman rank correlations. Statistical tests were two sided with significance threshold value of P , .05. The significance level was adjusted to P , .003 to compensate for multiple comparisons for associations of CSF GAP-43 and pathology severity across 17 brain regions.
Results
GAP-43 detection in brain and CSF by western blotting
To ensure specificity of the antibodies used for quantification of GAP-43 by ELISA, brain and CSF samples were processed for western blotting and GAP-43 was detected as a single band around 43 kDa in soluble and insoluble protein fractions of brain extracts by the antibodies NM4 and ABB-135 ( Supplementary Fig. 1A ). After immunoprecipitation of CSF with the same antibodies, a band corresponding to GAP-43 was detected aligning with that of recombinant GAP-43 ( Supplementary Fig. 1B ).
In-house ELISA characterization
Results from assay characterization are summarized in Supplementary Table 2 . CSF GAP-43 quantification with NM4-ABB135 immunoassay was stable after one to four freeze thaw cycles (n 5 9; 100.9%-107.9%), and various storage temperatures (n 5 7; 94.8%-103.5%, percentage of 280 C stored aliquot concentration).
Two-fold increase of GAP-43 in AD pilot study
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Demographics of clinical validation study
Demographics of participants in the validation study are provided in Table 1 . The clinical AD group was age and gender matched to controls and MCI patients. Age correlated weakly with CSF GAP-43 across the study population (r s 5 0.11, P 5 .004), but not in separate clinical diagnostic groups. Across all diagnostic groups, GAP-43 concentrations were higher in females than in males (median female: 2880 pg/mL, median male: 2547 pg/mL, P 5 .001) and remained significant only in the AD group after division by clinical diagnosis (median AD female: 3489 pg/mL, median AD male: 3023 pg/mL, P 5.017). No statistically significant differences in GAP-43 concentrations were detected based on ethnicity, education years, handedness, or MAPT H1/ H2 haplotypes.
CSF GAP-43 concentration in AD and MCI patients
CSF GAP-43 concentrations were significantly increased in clinical AD patients compared to controls (P ,.0001), but not in clinical MCI patients (Fig. 1A) . Of all the patients included in the study, 56 had a definitive Alzheimer's neuropathological diagnosis, and there was a trend toward increased CSF GAP-43 concentrations in this group compared to clinical AD. To identify possible clinical misdiagnosed patients, a neurochemical cutoff based on the INNO-BIA AlzBio3 T-tau/Ab 42 ratio (AD positive: ratio .0.48, T-tau: 93 pg/mL and Ab 42 : 192 pg/mL) suggested by Shaw et al [29] was applied to the clinical AD group. The ratio identified 209 biomarker-defined AD biomarkerpositive patients out of the 275 clinically diagnosed patients and CSF GAP-43 concentrations were significantly higher in AD biomarker-positive compared to biomarker-negative clinical AD patients (P , .001, Fig. 1B) . Furthermore, patients without a positive T-tau/Ab 42 ratio displayed GAP-43 concentrations equal to controls (Fig. 1B) . MCI patients were similarly divided by the T-tau/Ab 42 cutoff, and the biomarker-positive MCI group had significantly increased CSF GAP-43 concentrations compared to the biomarkerpositive MCI group (P , .0001, Fig. 1C ).
CSF GAP-43 concentration in AD differential diagnoses
Apart from AD patients, only lvPPA patients had altered CSF GAP-43 concentration compared to controls (P 5 .01, Fig. 1F ). The CSF GAP-43 concentrations in AD patients were compared in three subgroups of differential diagnoses: (1) Parkinsonian disorders and Parkinson's disease; (2) ALS; and (3) atypical AD and subgroups of FTD diagnoses.
CSF GAP-43 concentrations in clinical AD patients were significantly increased compared to both Parkinson's disease and Parkinsonian disorders (nondemented P 5 .0002, demented P 5 .027, with MCI; P 5 .0002), DLB (P 5 .018), and progressive supranuclear palsy (P 5 .0004), while there were no differences in the concentrations between AD and corticobasal syndrome patients (P . .99, Fig. 1D ). Eighteen percent of corticobasal syndrome patients had a T-tau/Ab 42 ratio indicative of AD. ALS (P , .0001) and bvFTD (P , .0001) both had significantly lower GAP-43 concentrations compared to AD (Fig. 1E and F) . The ALS patients with additional MCI or additional FTD were not significantly different from AD patients (P . .999 and P 5 .138, respectively, Fig. 1E ).
The FTD spectrum includes several related disorders in which progressive degeneration of the frontal and temporal lobes is common [30, 31] . On the basis of clinical phenotypes, we compared AD to FTD subgroups and atypical AD; PCA, bvFTD, and PPA of which the later was further divided into naPPA, lvPPA, and svPPA [30] . naPPA had significantly lower GAP-43 concentrations (P 5 .022, Fig. 1F ), whereas PCA (P 5 .182), lvPPA, and svPPA patients had similar CSF GAP-43 concentrations as AD patients (both P . .99, Fig. 1F ). Seventy percent of patients with lvPPA and 13% of patients with svPPA had T-tau/ Ab 42 ratios indicative of AD.
CSF GAP-43 concentration correlates with core AD biomarkers
Biomarker correlations were performed in patient groups with at least 10 patients and are presented in detail in Table 2 .
Strong correlations were found between GAP-43 and T-tau in all clinical groups. Furthermore, GAP-43 correlated moderately with P-tau in MCI patients, AD, ALS, DLB, progressive supranuclear palsy, PD with MCI, and weakly in FTD patients and controls. A weak negative correlation was found between GAP-43 concentration and Ab 42 in clinical AD and surprisingly a moderate positive correlation with Ab 42 in ALS patients (Table 2) . 512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578   579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594 compared to 0 Braak scores (P 5 .001, n 5 91, Fig. 3A) . Furthermore, GAP-43 correlated with CERAD score of Ab deposition across all diagnostic groups (r s 5 0.37, P ,.0001) and was significantly higher for score C compared to 0 (P 5 .001, n 5 92, Fig. 3B ). GAP-43 concentration was negatively correlated to brain weight (r s 5 20.30, P 5 .003, n 5 94) but not associated to hippocampal sclerosis. Examination and scoring of tau, thioflavin/amyloid, asynuclein and TDP-43 pathology, amyloid angiopathy, gliosis, and neuron loss carried out in 17 brain regions revealed that CSF GAP-43 concentration was specifically associated with AD pathology. GAP-43 concentration increased significantly with severity scores of tau pathology in the CA/subiculum hippocampus region, occipital cortex, and amygdala (Fig. 3C, D, and I) , and severity of both tau and amyloid pathology in the angular gyrus, superior-midtemporal cortex, and anterior cingulate cortex (Fig. 3E-H, J and K) . In the midfrontal cortex, GAP-43 increased with only tau pathology and gliosis ( Fig. 3L and M) . No difference was found in GAP-43 concentration across the severity grades of a-synuclein, amyloid angiopathy, and TDP-43 pathology in any brain region.
CSF GAP-43 concentration in APOE ε4 carriers
GAP-43 concentration was higher in subjects with one or two APOE ε4 alleles compared to subjects with no APOE ε4 alleles (0 vs. 1; P , .0001, vs. 2; P , .0001, Fig. 4A ). There was also a statistically significant decrease in GAP43 concentration in subjects with one or two APOE ε3 alleles compared to subjects with no APOE ε3 allele (0 vs. 2; P 5 .0001, 1 vs. 2; P , .0001, Fig. 4B ). When stratified based on clinical diagnosis, GAP-43 was only increasing with the number of APOE ε4 alleles in AD patients (n 5 236, P 5.022, n (0) 5 94, n (1) 5 106, n (2) 5 36; pairwise comparison: 0 vs. 1; P 5 .028, vs. 2; P 5 .046, Fig. 4C ) and MCI patients (P 5.038, n (0) 5 43 n (1) 5 23, n (2) 5 3, pairwise comparison 0 vs. 1; P 5 .03, vs. 2; P 5 .242, Fig. 4D ), but not in the other neurodegenerative diseases or controls.
Discussion
In this study, we quantified CSF GAP-43 in patients with different neurodegenerative dementias, including for the first time a large number of neuropathologically confirmed AD patients and important differential diagnoses such as several frontotemporal dementia diagnoses and PD and Parkinsonian disorders. Our results are in line with previous findings reporting increased CSF GAP-43 levels in AD [23, 24] , and patients with MCI due to AD [23] . However, the GAP-43 increase was more pronounced in our study compared to two previous studies [24, 25] , which may be due to assay differences or mixed patient cohorts at the time. We showed that GAP-43 can be reliably quantified in CSF by a novel in-house sandwich ELISA. Importantly, using this cohort, we show that CSF GAP-43 is associated with AD pathology, specifically increased in patients with high Braak neurofibrillary tangle stages and CERAD scores and in patients with moderate to severe tau and Ab neuropathology, particularly in the hippocampus, amygdala, temporal and occipital lobe. As there was only one association to gliosis and no associations to the extent of TDP-43, a-synuclein, or amyloid angiopathy, we conclude that these pathologies have no major influence on GAP-43 CSF concentration. These findings suggest that CSF GAP-43 could be an ADspecific biomarker as the concentrations follow amyloid and tau deposition in the brain and is not increased to the same extremes in any other neurological disease tested here. The positive correlation of GAP-43 with biomarker levels of T-tau and P-tau and the negative correlation with Ab 42 are in line with the findings of increased GAP-43 concentration with increased severity of tau and amyloid deposition in the brain. This indicates that there is a specific association between synaptic, tau, and amyloid pathology in AD; however, the biological connection between the three is yet to be demonstrated. Furthermore, low MMSE score and decline in MMSE score over time were weakly associated to higher GAP-43 concentration when analyzed in all the groups. The lack of association in subgroups may be due to several converging factors. GAP-43 concentrations could be saturated in Alzheimer's disease patients resulting in a lack of correlation to MMSE change over time. As GAP-43 is a regulator of synaptic plasticity and regenerative axonal growth and induced by both injury and cognitive stimulation [18, 19, 32] , there is also a possibility that GAP-43 increases with improvement in MMSE. Further studies are necessary to clarify this. GAP-43 was specifically increased in AD when compared to most other dementia disorders analyzed, and therefore, it could become useful for differential diagnosis. However
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, corticobasal syndrome patients, PCA and lvPPA and svPPA were not different from AD which is expected as these clinical syndromes usually have underlying AD pathology [1, [33] [34] [35] . Several of these patients had a neurochemical T-tau/Ab 42 ratio indicative of AD pathology which may partly explain the elevated CSF GAP-43 concentrations. For comparison, a study by Lee et al reported presence of AD pathology in 32% of clinical corticobasal syndrome patients, whereas 17% of these patients in our study had a positive AD biomarker profile [35] . A substantial proportion of patients with variants of primary progressive aphasia are known to display AD pathology [36, 37] , and CSF biomarker profile, based on Ab 42 / Ab 40 , PIB PET, T-tau, and P-tau analysis [38] [39] [40] . The low number of patients in the PCA group makes it inappropriate to draw definite conclusions regarding this group.
It has been reported that evaluations of novel biomarkers may underestimate their potential due to a proportion of clinically misdiagnosed patients. Several studies suggest an increased accuracy of the diagnosis, based on simultaneous neuropathological assessment or when using neurochemical cutoffs based on tau and Ab 42 quantification [1, 29] . We applied a neurochemical T-tau/Ab 42 ratio cutoff described in the study by Shaw et al, to reclassify the clinical AD patients. The biomarker-positive AD group had GAP-43 concentrations similar to the neuropathologically confirmed AD group indicating a valid classification. The neurochemical division of the MCI patients indicates that GAP-43 may be useful to predict conversion from MCI to AD; future longitudinal studies should address this further.
Unexpectedly, there was a strong positive correlation of GAP-43 concentration with Ab 42 selectively in ALS patients. Peripheral levels of amyloid precursor protein and Ab species have been reported to increase with disease onset in both ALS mouse models and patients and suggested to be directly involved in nerve degeneration [41] [42] [43] . This finding could also reflect that this is the only disease group included which does not have significant Ab pathology (only 7.5% biomarker-positive ALS patients) and CSF concentrations of Ab 42 and GAP-43 are the result of secretion in normally functioning synapses. Possibly, the GAP-43 concentration reflects a concurrent increase with Ab 42 concentration in ALS patients due to neurodegeneration; however, neither biomarker reaches the level of AD patients.
Furthermore, GAP-43 was especially high in AD and MCI patients who were also APOE ε4 carriers, suggesting that this phenotype is connected to an early synaptic vulnerability leading to the early cognitive decline.
In conclusion, CSF concentration of the presynaptic protein GAP-43 is specifically increased in tau-and amyloidpositive individuals and could therefore be used as a marker of synaptic dysfunction in AD, provide an additional outcome measure in clinical trials, and help to separate patients with AD from patients with other forms of neurodegenerative diseases. 
Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.jalz.2018.08.006.
RESEARCH IN CONTEXT
1. Systematic review: We reviewed studies investigating the presynaptic protein growth-associated protein 43 (GAP-43) in cerebrospinal fluid (CSF) as a biomarker for Alzheimer's disease, identifying five research articles using the search terms "GAP-43," "cerebrospinal fluid," and "Alzheimer's" in the PubMed database. One exploratory study indicated that CSF GAP-43 may be increased in preclinical Alzheimer's disease and another suggested a decrease in Parkinson's disease although no larger biomarker study was conducted.
2. Interpretation: Our findings suggest that CSF GAP-43 concentration is specifically associated to Alzheimer's disease pathology and correlated with cognitive decline, whereas no connection was found to the extent of a-synuclein and TDP-43 pathology.
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